Baseline Correlates of Complete Response to Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy in Patients with Relapsed and Refractory Multiple Myeloma: Subanalysis of the KarMMa Trial

被引：8
|
作者：
Shah, Nina [1 ]
Munshi, Nikhil C. [2 ]
Berdeja, Jesus G. [3 ,4 ]
Jagannath, Sundar [5 ]
Finney, Olivia [6 ]
Martin, Nathan [7 ]
Agarwal, Amit [7 ]
Rowe, Everton [7 ]
Campbe, Timothy B. [7 ]
San-Miguel, Jesus F. [8 ]
机构：
[1] UCSF, Med Ctr, San Francisco, CA USA
[2] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA
[3] Tennessee Oncol, Nashville, TN USA
[4] Sarah Cannon Canc Ctr, Nashville, TN USA
[5] Mt Sinai Med Ctr, New York, NY USA
[6] Bluebird bio, Cambridge, MA USA
[7] Bristol Myers Squibb, Princeton, NJ USA
[8] Univ Navarra Clin, CIMA, CIBERONC, IDISNA, Pamplona, Spain
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-148375
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1739
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis
    Berdeja, Jesus G.
    Raje, Noopur S.
    Siegel, David S.
    Lin, Yi
    Anderson, Larry D., Jr.
    Rodriguez-Otero, Paula
    Manier, Salomon
    Einsele, Hermann
    Cavo, Michele
    Truppel-Hartmann, Anna
    Rowe, Everton
    Sanford, Jill
    Wang, Julie
    Campbell, Timothy B.
    Jagannath, Sundar
    BLOOD, 2020, 136
  • [22] Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma: Updated Results from Phase 1 CRB-401 Study
    Lin, Yi
    Raje, Noopur S.
    Berdeja, Jesus G.
    Siegel, David S.
    Jagannath, Sundar
    Madduri, Deepu
    Liedtke, Michaela
    Rosenblatt, Jacalyn
    Maus, Marcela V.
    Massaro, Monica
    Petrocca, Fabio
    Caia, Andrea
    Yang, Zhihong
    Campbell, Timothy B.
    Hege, Kristen
    Munshi, Nikhil C.
    Kochenderfer, James N.
    BLOOD, 2020, 136
  • [23] Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma: Analyses of High-Risk Subgroups in the KarMMa Study
    Raje, Noopur S.
    Siegel, David S.
    Jagannath, Sundar
    Lonial, Sagar
    Munshi, Nikhil C.
    Moreau, Philippe
    Goldschmidt, Hartmut
    Cavo, Michele
    Truppel-Hartmann, Anna
    Rowe, Everton
    Huang, Liping
    Agarwal, Amit
    Wang, Julie
    Campbell, Timothy B.
    San-Miguel, Jesus F.
    Reece, Donna E.
    BLOOD, 2020, 136
  • [24] Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma
    Minakata, Daisuke
    Ishida, Tadao
    Ando, Kiyoshi
    Suzuki, Rikio
    Tanaka, Junji
    Hagiwara, Shotaro
    Ananthakrishnan, Revathi
    Kuwayama, Shigeki
    Nishio, Mitsufumi
    Kanda, Yoshinobu
    Suzuki, Kenshi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 117 (05) : 729 - 737
  • [25] Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma
    Daisuke Minakata
    Tadao Ishida
    Kiyoshi Ando
    Rikio Suzuki
    Junji Tanaka
    Shotaro Hagiwara
    Revathi Ananthakrishnan
    Shigeki Kuwayama
    Mitsufumi Nishio
    Yoshinobu Kanda
    Kenshi Suzuki
    International Journal of Hematology, 2023, 117 : 729 - 737
  • [26] Efficacy and Safety of Idecabtagene vicleucel (ide-cel, bb2121) in Elderly Patients (Pts) with Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa Subgroup Analysis
    Einsele, Hermann
    Berdeja, Jesus
    Raje, Noopur
    Siegel, David
    Lin, Yi
    Anderson, Larry, Jr.
    Rodriguez-Otero, Paula
    Manier, Salomon
    Cavo, Michele
    Truppel-Hartmann, Anna
    Rowe, Everton
    Sanford, Jill
    Wang, Julie
    Campbell, Timothy
    Jagannath, Sundar
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 53 - 53
  • [27] Characteristics of neurotoxicity associated with idecabtagene vicleucel (ide-cel, bb2121) in patients with relapsed and refractory multiple myeloma in the pivotal phase 2 KarMMa study
    Weisel, K.
    Manier, S.
    Kansagra, A.
    Anderson, Jr L. D.
    Berdeja, J.
    Jagannath, S.
    Lin, Y.
    Lonial, S.
    Shah, N.
    Raje, N.
    Siegel, D.
    Oriol, A.
    Truppel-Hartmann, A.
    Rowe, E.
    Patel, P.
    Agarwal, A.
    Campbell, T. B.
    Rodriguez-Otero, P.
    Munshi, N.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 179 - 180
  • [28] Subsequent Anti-Myeloma Therapy after Idecabtagene Vicleucel (ide-cel, bb2121) Treatment in Patients with Relapsed/Refractory Multiple Myeloma from the KarMMa Study
    Rodriguez-Otero, Paula
    San-Miguel, Jesus F.
    Anderson, Larry D., Jr.
    Lonial, Sagar
    Truppel-Hartmann, Anna
    Sanford, Jill
    Rowe, Everton
    Campbell, Timothy B.
    Munshi, Nikhil C.
    BLOOD, 2021, 138
  • [29] Efficacy and safety of Idecabtagene Vicleucel (ide-cel, bb2121) in elderly patients (Pts) with relapsed and refractory multiple myeloma (RRMM): KarMMa subgroup analysis
    Einsele, H.
    Berdeja, J.
    Raje, N. S.
    Siegel, D. S.
    Lin, Y.
    Anderson, L. D., Jr.
    Rodriguez-Otero, P.
    Manier, S.
    Cavo, M.
    Truppel-Hartmann, A.
    Rowe, E.
    Sanford, J.
    Wang, J.
    Campbell, T. B.
    Jagannath, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 198 - 199
  • [30] Idecabtagene vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma (RRMM): Analyses of High-Risk Subgroups in the KarMMa Study
    Goldschmidt, Hartmut
    Raje, Noopur
    Siegel, David
    Jagannath, Sundar
    Lonial, Sagar
    Munshi, Nikhil
    Moreau, Philippe
    Cavo, Michele
    Truppel-Hartmann, Anna
    Rowe, Everton
    Huang, Liping
    Agarwal, Amit
    Wang, Julie
    Campbell, Timothy
    San-Miguel, Jesus
    Reece, Donna
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 50 - 50
12345